To the central content area :::

TPEx

Listed Companies

:::
:::Listed Companies > Listed Companies Info. > Emerging Stock Board Companies > Listed Company Profile

ESM Companies

For foreign Emerging Stock Board enterprises, ”*- country of incorporation” indicates stocks without par value or with par value other than NT$10, and ”- country of incorporation” indicates stocks with par value of NT$10 per share.
6976 Acepodia
中文
Basic information
Chairman President Spokesperson Telephone Address ESM Registration Date
Patrick Yuhmin Yang Shih-Chia Hsiao Yanda Lai 02-2697-6100 17F.-12, No. 99, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei CityTaipei,Taiwan 2023/08/08
Agent for litigious
and non-litigious matters
Tel of
Agent for litigious
and non-litigious matters
Address of
Agent for litigious
and non-litigious matters
Shih-Chia Hsiao 0226976100 17F.-12, No. 99, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei City
Industry
category
Key businesses
Biotechnology and Medical Care Acepodia is a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform technology to address gaps in cancer care. Leveraging its ACC technology, the company links tumor-targeting antibodies to its proprietary immune cells, such as natural killer and gamma delta T cells to create novel ACE therapies, which have increased binding strength against tumors that express low levels of tumor antigens. Acepodia is made up of seasoned leaders and scientific experts dedicated to advancing its robust pipeline of ACE therapies with the potential to bring innovative, effective, and affordable cell therapies to a broad population of patients across a variety of solid tumors and hematologic cancers.
 
Market info
Latest trading info Historic trading info
 
Financial data
Cash flows statement Item
Amount(NTD, in thousands)
Cash flows from operating activities
Cash flows from investing activities
Cash flows from financing activities
Consolidated/Individual
balance sheet
Current assets
Non-current assets
Total assets
Current liabilities
Non-current liabilities
Total liabilities
Share capital
Capital surplus
Retained earnings
Other equity interest
Treasury shares
Total equity attributable to owners of parent
Non-controlling interests
Total equity
Book Value per share(NT$)
Consolidated/Individual
profit and loss
statement
Operating revenue
Operating costs
Gross profit from operations
Operating expenses
Net other income (expenses)
Net operating income
Non-operating income and expenses
Profit before tax
Tax expense
Profit from continuing operations
Profit from discontinued operations
Profit
Other comprehensive income
Comprehensive income
Basic earnings per share
 Auditor's report on latest financial statements: auditor's report:
 Investors may find more detailed information on the company by visiting the Market Observation Post System.。
 The information disclosed here concerning foreign enterprises consists of amounts provided in consolidated financial statements.